Bio-Rad Q2 revenue $691M down 3.5% YoY; non-GAAP EPS $3.38; raises FY22 revenue outlook; adds $200M buyback

BIO-RAD LABORATORIES, INC.

2022-Q2 EPS reported -$143.88 revenue$1,391,161,000

Q2 GAAP net loss $927M ($31.12/diluted) vs income $914M ($30.32) last year; non-GAAP net income $101M ($3.38) vs $107M ($3.54).
Reported sales $691.1M down 3.5% YoY; currency-neutral core sales (ex-COVID) up 5.7%.
Life Science $322M (-3.5% reported, +0.5% constant); Clinical Diag $368M (-3.3%, +0.7% constant).
FY22 guidance: non-GAAP currency-neutral revenue growth at high end of 1-2%; COVID rev ~$93M (up); op margin ~19% reaffirmed.
Board authorized additional $200M share repurchase; total available $298.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.